Kantar, Health Division, 175 Greenwich St, WTC 3, 35th Floor, NY 10007, USA.
Future Oncol. 2020 Mar;16(7):255-262. doi: 10.2217/fon-2019-0812. Epub 2020 Feb 5.
To report the results of a survey of USA physicians (CancerMPact) that treat non-small-cell lung cancer patients. 60 physicians were surveyed. Questions covered aspects of the treatment for all stages of the disease. For stage I patients, over 70% of the treatments were based on surgery. For stage II/III disease, a strong preference for combined therapy (surgery/radiation/systemic therapy) was observed. For advanced/stage IV patients, physicians used systemic therapy alone, and choosed the regimen based on histology and biomarkers. Use of PD-L1 inhibitors was highly dependent on histology and biomarkers. The treatment choices of non-small-cell lung cancer are increasingly complex, involve different treatment modalities and are highly dependent on histology and biomarkers, besides stage.
报告一项针对治疗非小细胞肺癌患者的美国医生（CancerMPact）的调查结果。共调查了 60 名医生。问题涵盖了疾病各个阶段治疗的各个方面。对于 I 期患者，超过 70%的治疗方法基于手术。对于 II/III 期疾病，强烈倾向于联合治疗（手术/放疗/全身治疗）。对于晚期/IV 期患者，医生单独使用全身治疗，并根据组织学和生物标志物选择方案。PD-L1 抑制剂的使用高度依赖于组织学和生物标志物。非小细胞肺癌的治疗选择越来越复杂，涉及不同的治疗方式，并且高度依赖于组织学和生物标志物，除了分期。
